Jose Recinos/iStock via Getty Images The U.S. FDA approved the supplemental New Drug Application for Scilex Holdings' ( NASDAQ: SCLX ) Gloperba, a liquid, oral of colchicine for the prophylaxis of gout flares in adults.

The company will launch the drug this month. It will cost $595 for a 150 mL bottle. Scilex noted that although colchine is currently available in a 0.

6 mg tablet or capsule, many gout patients have chronic kidney disease or gastrointestinal sensitivity making a lower dose preferable. The liquid version will allow providers to prescribe precision dosing. More on Scilex Holding Company Scilex wins court approval for Takeda settlement Scilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattack Seeking Alpha’s Quant Rating on Scilex Holding Company Historical earnings data for Scilex Holding Company Financial information for Scilex Holding Company.